Navigation Links
FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
Date:3/12/2013

RESEARCH TRIANGLE PARK, N.C., March 12, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CMX001 for the prevention of cytomegalovirus (CMV) infection.  CMX001 is the company's broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Fast Track-designated drugs ordinarily qualify for priority review, thereby expediting the FDA review process.

CMX001 has completed Phase 2 clinical development for the prevention of CMV infection in adult hematopoietic stem cell transplant (HSCT) recipients.  Chimerix is preparing to initiate SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adult HSCT recipients, in 2013.  The company has previously received Fast Track designation for its CMX001 development programs for preemptive treatment of adenoviral disease in patients post HSCT and for the treatment of smallpox.

About Chimerix and CMX001
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need.  The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. 

Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients.  Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies.  Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections.  Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.   

Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA). 

Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.   

 


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pancreatic Cancer Action Network Opposes Sequestration Cuts To National Institutes Of Health & Cancer Research Grants
2. State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
3. Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
4. FDA Grants Orphan Drug Status To Eisais Lenvatinib
5. FDA Grants 510(k) clearance for new Fluke Biomedical ESA615 Electrical Safety Analyzer
6. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
7. Afraxis Grants Exclusive Global License to Genentech
8. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
9. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
10. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
11. New Jersey Health Foundation Commits $2 Million to Fund Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... 2017 operating results on Monday, August 7, 2017 after ... 5:00 p.m. ET. ... broadcast of the conference call by dialing 877-201-0168 or ... approximately 15 minutes prior to the call. A live ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/21/2017)... , July 21, 2017 Did you know that ... in 2016? Or that combined spending on brand medicines, generics and ... spending, with brands accounting for just half of this (7 percent)? ... two thirds of the world,s venture capital investments in high-growth biopharmaceutical ... ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners ... their continued efforts to provide innovative offerings to their healthcare partners. These solutions ... build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent ...
(Date:7/26/2017)... ... ... time to sign up for the new One-A-Month Essential Oil Club for fun and ... Naturals and author of numerous books on essential oils. , , ... , Two items are included in the December mailing. , A ...
(Date:7/26/2017)... Michigan (PRWEB) , ... July 26, 2017 , ... ... appointed Medical Director for the treatment program located in Royal Oak, Michigan. ... of investors who are focused on providing the highest standards in the field of ...
(Date:7/26/2017)... ... 2017 , ... The number of adults 65 years or older is expected ... asthma control in the population are not well described. In a study published in ... journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors ...
Breaking Medicine News(10 mins):